A detailed history of Chatham Capital Group, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Chatham Capital Group, Inc. holds 21,595 shares of BMY stock, worth $1.28 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
21,595
Previous 21,595 -0.0%
Holding current value
$1.28 Million
Previous $896,000 24.67%
% of portfolio
0.19%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

SELL
$47.98 - $54.4 $23,990 - $27,200
-500 Reduced 2.26%
21,595 $1.17 Million
Q4 2023

Jan 19, 2024

SELL
$48.48 - $57.85 $4,508 - $5,380
-93 Reduced 0.42%
22,095 $1.13 Million
Q4 2022

Jan 31, 2023

SELL
$68.48 - $81.09 $37,664 - $44,599
-550 Reduced 2.42%
22,188 $1.6 Million
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $6,753 - $7,438
93 Added 0.41%
22,738 $1.75 Million
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $135,147 - $157,550
-2,520 Reduced 10.01%
22,645 $1.41 Million
Q1 2021

Apr 29, 2021

BUY
$59.34 - $66.74 $845,595 - $951,044
14,250 Added 130.55%
25,165 $1.59 Million
Q4 2020

Jan 27, 2021

BUY
$57.74 - $65.43 $25,983 - $29,443
450 Added 4.3%
10,915 $677,000
Q3 2020

Oct 22, 2020

BUY
$57.43 - $63.64 $57,430 - $63,640
1,000 Added 10.57%
10,465 $631,000
Q2 2020

Jul 20, 2020

BUY
$54.82 - $64.09 $28,506 - $33,326
520 Added 5.81%
9,465 $557,000
Q1 2019

May 09, 2019

SELL
$45.12 - $53.8 $4,512 - $5,380
-100 Reduced 1.11%
8,945 $427,000
Q4 2017

Feb 01, 2018

BUY
$59.94 - $65.35 $95,904 - $104,559
1,600 Added 21.49%
9,045 $554,000
Q2 2017

Aug 09, 2017

BUY
N/A
7,445
7,445 $415,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Chatham Capital Group, Inc. Portfolio

Follow Chatham Capital Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chatham Capital Group, Inc. with notifications on news.